56. Behcet disease Clinical trials / Disease details


Clinical trials : 76 Drugs : 110 - (DrugBank : 32) / Drug target genes : 36 - Drug target pathways : 116

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-002264-41-FR
(EUCTR)
19/07/2017NA Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Infliximab to that of Cyclophosphamide in severe Behçet's disease - ITAC Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease
MedDRA version: 20.0;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000017240 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Remicade 100 mg
Product Name: Remicade 100 mg
INN or Proposed INN: infliximab
Other descriptive name: infliximab
Trade Name: cyclophosphamide
Product Name: cyclophosphamide
INN or Proposed INN: cyclophosphamide
Other descriptive name: cyclophosphamide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNA Female: yes
Male: yes
52 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance